Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763899 | 0.89 | PREP (0.53) | PREPCA12CA1CA9 | |
| SCHEMBL23491348 | 0.82 | PREP (0.57) | PREPCA12CA1CA9 | |
| SCHEMBL20358470 | 0.82 | PREP (0.49) | PREPCA12CA1CA9 | |
| SCHEMBL6760799 | 0.82 | PREP (0.45) | PREPCA12CA1CA9 | |
| SCHEMBL3057447 | 0.80 | CA1 (0.50) | PREPCA12CA1CA9 | |
| SCHEMBL614621 | 0.80 | PREP (0.47) | PREPCA12CA1CA9 | |
| SCHEMBL8138379 | 0.80 | PREP (0.51) | PREPCA12CA1CA9 | |
| SCHEMBL6770995 | 0.78 | PREP (0.46) | PREPCA12CA1CA9 | |
| SCHEMBL5608460 | 0.78 | PREP (0.46) | PREPCA12CA1CA9 | |
| SCHEMBL173365 | 0.78 | PREP (0.49) | PREPCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029910-A1 | Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase | HANGWA CHEMICAL CORPORATION (KR) | 2004-02-12 | — | — | US | claimed |
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | claimed |
| EP-3642186-A1 | FLUORIDE FLUORESCENCE PROBE | The Procter and Gamble Company (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110785410-A | Fluorine ion fluorescent probe | 宝洁公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2018232675-A1 | FLUORIDE FLUORESCENCE PROBE | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1307198-A4 | PROTOBERBERINE DERIVATIVES WHICH INHIBIT ACTIVITY OF THE MITOGEN-ACTIVATED PROTEIN KINASE | HANWHA CHEMICAL CORP (KR) | 2007-07-11 | — | — | EP | disclosed |
| EP-0912571-B1 | NAPHTHYRIDINES WHICH AFFECT IL-4 AND G-CSF | SCHERING CORP (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6723860-B2 | 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1207162-B1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20040029910-A1 | Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase | HANGWA CHEMICAL CORPORATION (KR) | 2004-02-12 | — | — | US | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5190956-A | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections | SCHERING CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5179107-A | Herpes | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1992018507-A1 | ANTI-TUMOR AND ANTI-PSORIATIC AGENTS | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0508792-A1 | Anti-tumor and anti-psoriatic agents | SCHERING CORPORATION (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992004328-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004327-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029910-A1 | Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase | MAPK1, MAPK4, MAPKAPK2 | PREP 1987/4885CA12 4842/4885CA1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.